BioLineRX
BLRX
26 hedge funds and large institutions have $41M invested in BioLineRX in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 6 closing their positions.
24% more capital invested
Capital invested by funds: $33.1M → $41M (+$7.93M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
+$1.24M |
| 2 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$192K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$182K |
| 4 |
FWM
Focused Wealth Management
Newburgh,
New York
|
+$33K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$98K |
| 2 |
Morgan Stanley
New York
|
-$45.7K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$20.9K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$18.2K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
RE
27
RBC Europe
London,
United Kingdom
| $214 | – | – | – |
|
|
28
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$98K | -180 | Closed |
|
|
ARTA
29
A.R.T. Advisors
New York
| – | -$15K | -28 | Closed |
|
30
Ameriprise
Minneapolis,
Minnesota
| – | -$9K | -18 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$7K | -13 | Closed |
|
|
CF
32
Centaurus Financial
Anaheim,
California
| – | -$6K | -12 | Closed |
|
|
ML
33
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$3K | -6 | Closed |
|
BLRX Hedge Fund Activity: Q3 2018 in Review
26 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2018, worth a combined $41M — up 24% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BLRX positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Fosun International, opening a new position worth an estimated $1.24M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $98K sold.
- 26 institutional investors held BioLineRX (BLRX) as of Q3 2018, up from 25 in Q2 2018.
- Funds reported $41M of BioLineRX stock for Q3 2018, up 24% quarter-over-quarter.
- 7 funds opened new BioLineRX positions in Q3 2018 and 6 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2018 was Fosun International, an estimated $1.24M added.
- The largest BioLineRX seller in Q3 2018 was Susquehanna International Group, an estimated $98K sold.
Based on aggregated 13F filings for Q3 2018.